Zobrazeno 91 - 100
of 698
pro vyhledávání: '"John S"'
Autor:
David E.R. Sutherland, John S. Najarian, Raja Kandaswamy, Hassan N. Ibrahim, Abhinav Humar, William D. Payne, Arthur J. Matas, Kristen J. Gillingham, Ty B. Dunn, Rainer W.G. Gruessner
Publikováno v:
Transplantation. 85(3)
The benefits (e.g., low acute rejection [AR] rate) vs. the long-term risk of each immunosuppressive protocol may determine the protocol's value.We studied the long-term impact of new-onset posttransplant diabetes (PTDM) and/or AR in 1,487 adult, prim
Publikováno v:
Transplantation. 50:487-492
This study was designed to investigate aspects of renal xenobiotic metabolism and the renal cellular response to drug-induced injury, in mediating cyclosporine nephrotoxicity. The relation between CsA and renal enzyme activity has not previously been
Publikováno v:
Transplantation. 82(12)
Strategies to increase kidney transplantation are urgently needed.We studied all (n = 73,073) first kidney-only transplant recipients in the United States between 1995 and 2003 to determine the incidence and outcomes of living donor transplantation a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
R. Duane Davis, John S. Logan, Stephanie D. Love, Zoie E. Holzknecht, Aaron Lesher, Jeffrey G. Gaca, Jeffrey G. Lukes, James Z. Appel, William Parker, Gonzalo V. Gonzalez-Stawinski, Jeffrey L. Platt, Daniel Palestrant
Publikováno v:
Transplantation. 81(12)
Background. In contrast to renal or cardiac xenografts, the inhibition of complement using cobra venom factor (CVF) accelerates pulmonary xenograft failure. By activating C3/C5 convertase, CVF depletes complement while additionally generating C5a and
Autor:
Eva M. Vasquez, John S. Thompson, Raymond Pollak, Dar Shong Hwang, Thomas Waid, Judy Hyun Ju Jin, Mark D. Pescovitz, Donald E. Hricik, Duane G. Wombolt, R. Wong, Timothy L. Pruett, David I. Min, M. Gerry Choc, Gary Barone, James B. Stinson, Christopher L. Marsh, Jon B. Klein
Publikováno v:
Transplantation. 63:778-780
BACKGROUND The new microemulsion formulation of cyclosporine (CsA-ME) is more bioavailable than cyclosporine (CsA) in de novo renal transplant patients. Therefore, it was of interest to compare the safety profile of each formulation in such patients.
Autor:
John S. Thompson, Donald E. Hricik, C. Martin Bunke, Mark D. Pescovitz, Raymond Pollak, M. Gerry Choc, David I. Min, Eva M. Vasquez, James B. Stinson, Judy Hyun Ju Jin, Jon B. Klein, Christopher L. Marsh, R. Wong, Duane G. Wombolt, Thomas Waid, Timothy L. Pruett, Gary Barone
Publikováno v:
Transplantation. 61:968-970
A 12-week, randomized, double-blind, multicenter pharmacokinetic study was conducted to compare the clinical safety and tolerability of cyclosporine capsules and oral solution for microemulsion and cyclosporine in 101 primary renal transplant recipie
Autor:
Johannes Schirmer, John S. Logan, Marian G. Michaels, Christopher G.A. McGregor, Guerard W. Byrne, Henry D. Tazelaar, Randall C. Walker, Jack M. Risdahl, Sumeet S. Teotia
Publikováno v:
Transplantation. 78(11)
Background Animal organs could satisfy the demand for solid organ transplants, which currently exceeds the limited human donor supply. Hyperacute rejection, the initial immune barrier to successful xenotransplantation, has been overcome with pig dono
Publikováno v:
Transplantation. 78(6)
Background Preemptive kidney transplantation is associated with an allograft survival advantage and is promoted in part because of this association. The basis for the allograft survival advantage in preemptive recipients is unclear. Possibilities inc
Autor:
Steven, Paraskevas, Raja, Kandaswamy, Abhinav, Humar, Kristen, Gillingham, Rainer W G, Gruessner, William D, Payne, John S, Najarian, David L, Dunn, David E R, Sutherland, Arthur J, Matas
Publikováno v:
Transplantation. 75(8)
As short-term transplant results improve, it has become difficult to use patient or graft survival or acute rejection as clinical trial endpoints, except in large, multicenter studies. Despite better outcomes, graft failure continues over time.We stu